CCX140-B

DRUG5 trials

Sponsors

Amgen

Conditions

Diabetic NephropathyFSGSFocal Segmental GlomerulosclerosisGlomerulosclerosisType 2 Diabetes Mellitus

Phase 2

A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

CompletedNCT01028963

AmgenType 2 Diabetes Mellitus

Start: 2010-01-31End: 2010-11-30Updated: 2025-03-06

A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria

CompletedNCT01440257

AmgenDiabetic Nephropathy, Type 2 Diabetes Mellitus

Start: 2011-09-30End: 2013-09-30Updated: 2025-02-27

A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy

CompletedNCT01447147

AmgenDiabetic Nephropathy, Type 2 Diabetes Mellitus

Start: 2011-10-31End: 2014-12-31Updated: 2025-02-27

A Study of CCX140-B in Subjects With FSGS

CompletedNCT03536754

AmgenFocal Segmental Glomerulosclerosis, FSGS, Glomerulosclerosis

Start: 2018-05-17End: 2020-02-19Updated: 2025-03-13

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

TerminatedNCT03703908

AmgenFocal Segmental Glomerulosclerosis

Start: 2018-10-01End: 2020-06-24Updated: 2025-03-17

Related Papers

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.

2015-08-09210 citations